ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 287,500 common shares have been issued by the Company in exchange for €1,532,750.00 as the result of the exercise of warrants.

Dr Edwin Moses, CEO, exercised 287,500 warrants, of which he retained 67,500 as shares, increasing his total holding to 184,200 shares, with the proceeds of the rest of the exercised warrants being partly used to fund exercise costs and taxes. The majority of the exercised warrants were due to expire in 2016. In addition to his shareholding, Dr Moses still retains approximately 0.5 million granted warrants.

As a result of this transaction, Ablynx now has 54,812,374 shares outstanding.

The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,651,245 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies^®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  [email protected]
Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]

Pdf version of the press release http://hugin.info/137912/R/1974115/722236.pdf

HUG#1974115